Weight loss and engagement: January 2026 analysis of 14,203 Noom GLP-1 Rx Program members who started a GLP-1 Rx plan between December 2024 and February 2025 and logged weight during a measurement week (4, 8, 16, 40 weeks)
Patients using multi-dose pens should write the date of first use on their pen to track how long it has been in use
in patients with T2DM (38) found that continuous GLP-1 administration via a subcutaneous pump to raise serum GLP-1 levels from a mean of 9.7 pM at baseline to 282 pM over 6 weeks significantly reduced plasma glucose concentrations, improved glycated hemoglobin, and enhanced insulin sensitivity and -cell function compared to placebo, with no significant limiting side effects reported
Real-World Limitations: Insurance Barriers If the science is clear, why cant everyone access GLP-1
Drucker, D., Easley, C
The second accelerator is tirzepatides performance advantage crystallizing a new efficacy standard